Disease Registry Study Research Articles

Association of Damaged Cardiovascular-Bone-Skeletal Muscle Axis with All-Cause Mortality and CKD Progression in Patients with Predialysis CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Association of Damaged Cardiovascular-Bone-Skeletal Muscle Axis with All-Cause Mortality and CKD Progression in Patients with Predialysis CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Phosphate Loading per Nephron Predicts CKD Progression and All-Cause Death in Patients with Nondialysis-Dependent CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Phosphate Loading per Nephron Predicts CKD Progression and All-Cause Death in Patients with Nondialysis-Dependent CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Intraindividual Difference between Cystatin C- and Creatinine-Based eGFR Is Associated with All-Cause and Cardiovascular Mortality: The Fukuoka Kidney disease Registry (FKR) Study

Intraindividual Difference between Cystatin C- and Creatinine-Based eGFR Is Associated with All-Cause and Cardiovascular Mortality: The Fukuoka Kidney disease Registry (FKR) Study

Sex-Specific Relationships between Estimated Potassium Intake and Cardiovascular Outcomes in Patients with CKD: The Fukuoka Kidney Disease Registry Study

Sex-Specific Relationships between Estimated Potassium Intake and Cardiovascular Outcomes in Patients with CKD: The Fukuoka Kidney Disease Registry Study

Accurate non-ceruloplasmin bound copper: a new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS.

Assessment of Wilson disease is complicated, with neither ceruloplasmin, nor serum or urine copper, being reliable. Two new indices, accurate non-ceruloplasmin copper (ANCC) and relative ANCC were developed and applied to a cohort of 71 patients, as part of a Wilson Disease Registry Study. Elemental copper-protein speciation was developed for holo-ceruloplasmin quantitation using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry. The serum proteins were separated using gradient elution and measured at m/z 63 (63Cu+) and 48 (32S16O+) using oxygen reaction mode and Cu-EDTA as calibration standard. The ANCC was calculated by subtraction of the ceruloplasmin bound copper from the total serum copper and the RelANCC was the percentage of total copper present as the ANCC. The accuracy of the holo-ceruloplasmin measurement was established using two certified reference materials, giving a mean recovery of 94.2 %. Regression analysis between the sum of the copper containing species and total copper concentration in the patient samples was acceptable (slope=0.964, intercept=0, r=0.987) and a difference plot, gave a mean difference for copper of 0.38 μmol/L. Intra-day precision for holo-ceruloplasmin at serum copper concentrations of 0.48 and 3.20 μmol/L were 5.2 and 5.6 % CVand the intermediate precision at concentrations of 0.80 and 5.99 μmol/L were 6.4 and 6.4 % CV, respectively. The limit of detection (LOD) and lower limit of quantification (LLOQ) for holo-ceruloplasmin were 0.08 and 0.27 μmol/L as copper, respectively. ANCC and Relative ANCC are important new diagnostic and monitoring biomarker indices for Wilson disease (WD).

Relationships of Weight Change from 20 Years of Age with the Risks of All-Cause and Cardiovascular Mortality in Patients with Chronic Kidney Disease.

Weight changes from a young age are known to be associated with poor life outcomes in the general population. However, little is known about the association between weight change from a young age and life expectancy in patients with chronic kidney disease (CKD). Data of 2,806 nondialysis CKD patients who participated in the Fukuoka Kidney Disease Registry (FKR) Study, a multicenter observational study, were analyzed. The primary outcome was all-cause death, whereas the secondary outcome was cardiovascular mortality. The covariate of interest was weight change, defined as the difference between body weight at study enrollment and at 20 years old. Cox proportional-hazards models were used to estimate the risks of mortality for participants with weight changes of ≥ 5 or ＜5 kg compared with those with stable weights. During the 5-year observation period, 243 participants died from all causes and 62 from cardiovascular disease. The risk of all-cause mortality in the weight-loss group was significantly higher than that in the stable-weight group (multivariable-adjusted hazard ratio, 2.11; 95% confidence interval [CI], 1.52-2.93). Conversely, the risk of cardiovascular mortality in the weight-loss group was significantly higher than that in the stable-weight group (multivariable-adjusted hazard ratio, 2.48; 95% CI, 1.32-4.64). However, no significant association was observed between weight gain and the risks of all-cause and cardiovascular mortalities. Weight loss from 20 years of age was found to be associated with higher risks of all-cause and cardiovascular mortalities in patients with CKD.

Associations between air pollution and the onset of acute exacerbations of chronic obstructive pulmonary disease: A time-stratified case-crossover study in China

Associations between air pollution and the acute exacerbations of chronic obstructive pulmonary disease (AECOPD) have been established primarily in time-series studies in which exposure and case data were at the aggregate level, limiting the identification of susceptible populations. Are air pollutants associated with the onset of AECOPD in China? Who is more susceptible to the effects of air pollutants? AECOPD data were obtained from the Acute Exacerbation of Chronic Obstructive Pulmonary Disease Registry study and air pollution data were assigned to individuals based on their residential address. We adopted a time-stratified case-crossover study design combined with conditional logistic regression models to estimate the associations between six air pollutants and AECOPD. Stratified analyses were performed by individual characteristics, disease severity, COPD types, and the season of exacerbations. A total of 5,746 patients were finally included. At a 2-day lag, for each interquartile range increase in PM2.5 and PM10 concentrations, odds ratios for AECOPD were 1.054 (95% CI: 1.012, 1.097) and 1.050 (95% CI: 1.009, 1.092), respectively. The associations were more pronounced in participants who were aged < 65 years, had experienced at least one severe AECOPD in the past year, were first diagnosed with COPD between the ages of 20 and 50, and experienced AECOPD in the cool seasons. By contrast, significant associations for NO2, SO2, and CO lost significance when excluding cases collected before 2020 or with larger distance from the monitoring station, and no significant association was observed for O3. This study provides robust evidence that short-term exposure to PM2.5 and PM10 was associated with higher odds of AECOPD onset. Individuals who are young, have severe COPD or young COPD, and experience an exacerbation during the cooler seasons may be particularly susceptible. NCT2657525 (ClinicalTrials.gov).

Associations between the Serum Triglyceride Level and Kidney Outcome in Patients with Chronic Kidney Disease: The Fukuoka Kidney disease Registry Study.

Hypertriglyceridemia is a risk factor for chronic kidney disease (CKD). However, whether or not it predicts the risk of CKD progression is unknown. This study evaluated the association between serum triglyceride (TG) levels and kidney disease progression in patients with non-dialysis-dependent CKD. The Fukuoka Kidney disease Registry (FKR) study was a multicenter, prospective longitudinal cohort study. In total, 4,100 patients with CKD were followed up for 5 years. The primary outcome was the incidence of CKD progression, defined as a ≥ 1.5-fold increase in serum creatinine level or the development of end-stage kidney disease. The patients were divided into quartiles according to baseline serum TG levels under non-fasting conditions: Q1 ＜87 mg/dL; Q2, 87-120 mg/dL; Q3, 121-170 mg/dL, and Q4 ＞170 mg/dL. During the 5-year observation period, 1,410 patients met the criteria for CKD progression. The multivariable-adjusted Cox proportional hazards model showed a significant association between high serum TG level and the risk of CKD progression in the model without macroalbuminuria as a covariate (multivariable hazard ratio[HR] for Q4 versus Q1, 1.20; 95% CI, 1.03-1.41; P=0.022), but the significance disappeared after adjusting for macroalbuminuria (HR for Q4 versus Q1, 1.06; 95% CI, 0.90-1.24; P=0.507). The present findings suggest that individuals with high serum TG levels are more likely to develop CKD progression than those without; however, whether or not higher serum TG levels reflect elevated macroalbuminuria or lead to CKD progression via elevated macroalbuminuria is unclear.

The Association Between Higher Serum Triglyceride Level and Poor Kidney Outcome Among Patients with CKD: The Fukuoka Kidney Disease Registry (FKR) Study

The Association Between Higher Serum Triglyceride Level and Poor Kidney Outcome Among Patients with CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Estimated Potassium Intake in Patients with CKD Is Associated with CKD Progression: The Fukuoka Kidney Disease Registry (FKR) Study

Estimated Potassium Intake in Patients with CKD Is Associated with CKD Progression: The Fukuoka Kidney Disease Registry (FKR) Study

Cardiovascular Risk Factor Burden and Treatment Control in Patients with Chronic Kidney Disease: A Cross-Sectional Study.

Cardiovascular disease is a life-threatening chronic kidney disease (CKD) complication. Although cardiovascular risk factor management is significant in patients with CKD, there are few reports that detail the frequency of complications and the treatment of cardiovascular risk factors at different stages of CKD in clinical practice. There were a total of 3,407 patients with non-dialysis-dependent CKD who participated in the Fukuoka Kidney disease Registry Study, and they were cross-sectionally analyzed. The patients were classified into five groups based on their estimated glomerular filtration rate and urinary albumin to creatinine ratio according to Kidney Disease: Improving Global Outcomes 2012 guidelines, which recommend low, moderate, high, very high, and extremely high risk groups. The primary outcomes were the cardiovascular risk factor burden and the treatment status of cardiovascular risk factors. Using a logistic regression model, the association between the CKD groups and the treatment status of each risk factor was examined. The proportion of patients with hypertension, diabetes mellitus, and dyslipidemia significantly increased as CKD progressed, whereas the proportion of patients who achieved cardiovascular risk factor treatment targets significantly decreased. In the multivariable analysis, the odds ratios (ORs) of uncontrolled treatment targets were significantly higher for hypertension (OR 3.68) in the extremely high risk group than in the low risk group. Patients with non-dialysis-dependent CKD demonstrate an increased cardiovascular risk factor burden with greater severity of CKD. Extremely high risk CKD is associated with difficulty in managing hypertension.

Prevalence of hyponatremia and associated factors in patients with chronic kidney disease: the Fukuoka Kidney Disease Registry (FKR) study.

Hyponatremia is a common and important electrolyte disorder. However, the prevalence and factors associated with hyponatremia in patients with chronic kidney disease (CKD) are unknown. We studied the factors associated with hyponatremia (< 135mEq/L) in CKD patients registered in the Fukuoka Kidney Disease Registry (FKR) study using a logistic regression model variable selected using the variable reduction method. We analyzed the baseline characteristics of 4367 participants with CKD (age, 64 ± 16years; male, 56.1%). Hyponatremia was detected in 2.0% of the patients at baseline, and multivariate logistic analysis showed that the independent factors for hyponatremia were body mass index (odds ratio [OR] 0.91; 95% confidence interval [CI] 0.85-0.97), prescription of benzodiazepine (OR 2.31; 95% CI 1.39-3.86), blood hemoglobin level (OR 0.76; 95% CI 0.65-0.88), and serum C-reactive protein level (OR 1.27; 95% CI 1.04-1.54). The cross-sectional analysis using baseline data from the FKR study revealed independent factors associated with hyponatremia in patients with decreased kidney function. Longitudinal analyses of the FKR cohort are needed to evaluate the effects of these factors on the prognosis of hyponatremia in patients with CKD.

Angiotensin II receptor blockers and bone fracture in chronic kidney disease patients: the Fukuoka kidney disease Registry Study.

Angiotensin II receptor blockers (ARBs) reportedly reduce the risk of developing bone fractures; however, this association remains unclear among patients with chronic kidney disease (CKD). This was a cross-sectional study of 3380 CKD patients enrolled in the Fukuoka Kidney disease Registry Study, a multicenter prospective observational cohort study of non-dialysis-dependent CKD patients. The patients were divided into two groups, those taking ARBs and those who were not. Logistic regression models were used to examine the association between ARBs and bone fracture. Approximately 67.0% of the participants were on ARBs, and 6.3% had a history of bone fracture. The history of bone fracture was significantly lower in patients with prescribed ARB and remained significant even after multivariable adjustment (odds ratio, 0.68; 95% confidence interval, 0.51-0.93). Other antihypertensive drugs, such as thiazide diuretics, which were reportedly helpful in preventing fractures, did not alter the bone fracture history and did not change among ARB users and non-users. The present study showed that administering ARB was significantly associated with a lower frequency of bone fracture history.

A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924).

e13039 Background: Over the last decade the standard-of-care treatment for patients with HER2+ aBC has included anti-HER2 therapies often combined with chemotherapy. These approaches have shown efficacy in clinical trials which have recruited patients in restricted populations defined by lines of therapy and previous treatments. There are few data regarding the long-term outcomes of patients treated with these regimens, including those with brain metastases. We conducted a prospective, multicentre non-interventional study to observe anti-cancer treatment regimens and clinical outcomes in patients with HER2 positive aBC. Methods: Adult patients diagnosed with HER2-positive aBC within the last 6 months were included. No specific treatment approach or course was mandated by the protocol. Source data was taken from the patient’s chart and other medical records, then reported by means of an electronic data collection system. Data regarding treatment received, efficacy (progression-free and overall survival (PFS), response rates (RR) and development of CNS metastases) and safety (including cardiac toxicity) were captured. Results: Between February 2015 and April 2018, 311 eligible patients were recruited with median age 57 years (24-96). At diagnosis of aBC the most common distant metastatic sites were bone (n = 145;47%), liver (n=117;38%), lung (n=100;32%) and brain (n=21;7%). First line treatment was with pertuzumab (P)/trastuzumab(T)/chemotherapy (n=212;68%), T/chemotherapy (n=45;14%), other T combinations without P (n=19;6%), Trastuzumab Emtansine regimens without T or P (n=16;5%) (19; 5% other combinations). Patients’ status as of cut-off date for this analysis (28th Feb 2022, median follow-up 44.1 months) is shown. The median PFS of patients treated in the 1st, 2nd and 3rd lines was 26.7 months, 10.7 months and 8.6 months. At the time of this analysis an additional 60 patients (19%) had developed brain metastases during first line. The number of patients starting 2nd, 3rd and 4th line treatment with brain metastases were 28 (22%), 17 (40%), 7 (37%) respectively. Conclusions: In routine clinical practice, as reflected by this registry, at least 40% of patients who initiate first line therapy for advanced breast cancer do not proceed to 3rd line therapy, and brain metastases become increasingly common. These findings have implications for selection of optimal 2nd and 3rd line treatment. Clinical trial information: ISRCTN02393924 . [Table: see text]

The Association of Controlling Nutritional Status Score and Prognostic Nutritional Index with Cardiovascular Diseases: the Fukuoka Kidney Disease Registry Study.

The Controlling Nutritional Status (CONUT) score and the Prognostic Nutritional Index (PNI) reflect the immunonutritional status of patients. However, the associations of these two indices with cardiovascular disease (CVD) have not been characterized in patients with chronic kidney disease (CKD). Therefore, the current study aimed to determine whether the CONUT score or PNI was associated with prior CVD in patients with CKD. A cross-sectional study of 2,751 patients with CKD who were not on dialysis was performed. The patients were grouped into tertiles (T1-T3) of PNI and placed into three groups following their CONUT score: low- (CONUT score, 0), mild- (CONUT score, 1-2), and moderate-to-high- (CONUT score, ≥ 3) risk groups. Prior CVD was present in 655 (24%) of the participants. Multivariable logistic regression analyses, with adjustment for potential confounders, showed that high CONUT score was associated with prior CVD than the low score (mild-risk group: odds ratio [OR]=1.35, 95% confidence interval [CI]=1.04-1.76; moderate-to-high-risk group: OR=1.66, 95% CI=1.19-2.30). In addition, the lower PNI tertiles were independently associated with prior CVD compared with T3 of PNI (T1: OR=1.45, 95% CI=1.09-1.92; T2: OR=1.32, 95% CI=1.01-1.72). Both CONUT score and PNI were found to be independently associated with prior CVD in patients with CKD in the present cross-sectional study. A longitudinal study is needed to elucidate whether these two indices are associated with subsequent cardiovascular events.

Abstract P3-02-05: Interim Analysis Results from a European Disease Registry Study Aimed to Prospectively Observe Treatment Patterns and Outcomes in Patients with HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer

Abstract BACKGROUND: Metastatic breast cancer (MBC) is incurable, with the primary goal of treatment being to extend survival while preserving quality of life. Treatment options available to patients (pts) with human epidermal growth factor receptor-2 positive breast cancer (HER2+ BC) may vary between countries, in terms of both the drugs used and the sequence in which they are used. There is limited data available on the clinical characteristics and outcomes in pts with unresectable locally advanced (LA) BC. This study aimed to capture real-world data on treatment patterns and clinical outcomes in HER2+ unresectable LABC and MBC. METHODS: SAMANTHA (NCT02913456) is an ongoing, prospective, multicentre non-interventional study designed to observe pts with HER2+ unresectable LABC or MBC for a period of up to 8 years on study. The primary objectives are progression-free survival (PFS), assessed according to standard medical practice, and the treatment received. Secondary objectives included overall survival (OS), duration of response and safety. This pre-planned interim analysis reports baseline characteristics, treatment regimens received, first-line (1L) PFS by advanced BC status and the incidence of adverse events (AEs). RESULTS: The study enrolled 647 pts from five European (EU) countries (Nov 2016-Nov 2019); 629 received 1L treatment and were included in data analysis. At data cut-off date (16 Nov 2021), median follow-up on study was 30.4 months (mo; range: 0.1; 60.0); 342 (54%) pts discontinued 1L treatments, of whom 170 (50%) pts received 2L treatments, 74 pts died, 49 pts were lost to follow-up, 35 pts withdrew consent and 14 pts withdrew due to physician decision. The full analysis set (FAS) included 222 (35%) LABC pts and 407 (65%) MBC pts [Table]. Pertuzumab/trastuzumab based regimens were given as 1L in the majority of pts [462 (73 %)]. The FAS Median (m) PFS in 1L was 41.3 mo (95% CI: 36.1, 54.1) for LABC and 23.5 mo (95% CI: 20.6, 27.6) for MBC. Median OS was not reached. In the FAS, any AEs were reported in 352 (56%) pts; of these 212 (34%) had a grade 3 or higher AE. Serious (S) AEs were reported in 135 (22%) pts; of whom, 36 (6%) pts had treatment related SAEs. CONCLUSIONS: This interim analysis of SAMANTHA provides a snapshot of LABC/MBC treatment practices in five EU countries, where pertuzumab/trastuzumab based regimens appear to be the most used 1L treatment options, which aligns with the recommended standard of care. The mPFS is consistent with previous literature although higher than what was reported in the pivotal clinical trial CLEOPATRA. Given the good outcome observed in 1L and the current follow-up period of 30.4 mo, the data are not yet mature enough to provide complete insights into the treatment sequencing patterns and the clinical outcomes associated with these treatments. Acknowledgments: The study is sponsored by F. Hoffmann-La Roche Ltd. Table: Demographics and baseline disease characteristics of patients by status of advanced BC Citation Format: Marija Balic, Luis Costa, Joseline Ojaimi, Cristina Marinela Oprean, José L. Passos Coelho, Isabel Pazos, Fabio Puglisi, Thibaut Sanglier, Giuseppa Scandurra, Michael Schenker, Laurentia A. Wahyudi, Georgi Zhbantov, Constanta Timcheva. Interim Analysis Results from a European Disease Registry Study Aimed to Prospectively Observe Treatment Patterns and Outcomes in Patients with HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-02-05.

Heart failure in rheumatic heart disease, characteristics, and determinants: Himachal Pradesh rheumatic fever/rheumatic heart disease registry study

Heart failure in rheumatic heart disease, characteristics, and determinants: Himachal Pradesh rheumatic fever/rheumatic heart disease registry study

Low intake of β carotene and dietary fiber from vegetables and fruits in patients with chronic kidney disease

Patients with chronic kidney disease (CKD) occasionally need to restrict their consumption of vegetables and fruits. However, recent evidence suggests that plant-based diets have beneficial effects in patients with CKD. We aimed to determine the sufficiency of β carotene and dietary fiber intake in patients with CKD. We conducted a cross-sectional study among 4476 patients registered in the Fukuoka Kidney Disease Registry (FKR) study, a Japanese prospective cohort study of patients with CKD. Data from 3545 patients were analyzed after excluding cases with insufficient information. We evaluated the relationship between CKD stages and the intake of vegetables and fruits. The intake of β carotene and dietary fiber in CKD stages was evaluated using analysis of covariance. As the CKD stage advanced, the intake of vegetables, green leafy vegetables, and fruits significantly decreased (P-value for all trends < 0.01). The intake of vegetables significantly decreased as the CKD stage advanced (P for trend < 0.01). After adjusting for confounding factors, the intake of β carotene and dietary fiber also decreased (both P < 0.01) as the CKD stage advanced. Patients with CKD had insufficient vegetable and fruit intake and a lack of β carotene and dietary fiber from vegetables and fruits.

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Introduction: Elderly patients (≥ 61years [y]) with cHL have inferior outcomes compared to their younger counterparts. This group of patients (pts) accounts for 20-25% of the cHL cohort, but they are under-represented in clinical trials and there is no established optimal therapy. Given the heterogeneity of treatment and the paucity of data, we aimed to provide a snapshot of clinical presentations and contemporary front-line management of elderly Australian patients with cHL, as well as to explore patient and treatment factors associated with unplanned hospital admission and survival. Methods: cHL pts aged ≥61y, diagnosed from 2011-2022, were included. National data from the LaRDR were supplemented by additional detail information on toxicities, hospitalisation and long term survival from 7 Australian centres. Baseline demographics, disease characteristics, front-line management and response were combined from LaRDR and ALA datasets. Statistical analysis was performed on STATA v17. Chi square was utilised for univariate analysis on relevant categorical data relating to hospital admission and a multivariate analysis using logistic regression was built with significant variables identified. Survival analysis was conducted with Kaplan-Meier and univariate analysis was performed with a log-rank test. Clinically relevant parameters were included in a multivariate Cox proportional hazard model. Results: 195 pts were identified - 123 from ALA, 72 from LaRDR. Baseline characteristics are summarised in Table 1 and 2. Dataset: ALA and LaRDR (N=195) 91.3% pts commenced on chemotherapy, with anthracycline-based regimens used in 81%. 86.1% pts had ABVD-AVD, 5.7% CHOP, 5.1% PVAG, 3.2% other. Median number of cycles for stage I-II was 2 (range 0-6) and stage III-IV was 6 (range 0-8); 26.2% had radiotherapy. Response to front-line chemotherapy was complete remission (CR) 56.4%; partial remission (PR) 7.2%; stable disease (SD) 1.5%; progressive disease (PD) 7.2%; unknown 27.7%. Dataset: ALA (N=123) Of the 123 pts, 7 did not commence any therapy, 9 commenced therapy with a palliative intent. Of those who received therapy (n=116); 102 received anthracycline regimens and 66 received bleomycin. Initial therapy was ABVD in 64, AVD in 21, CHOP-like in 7, PVAG in 7, eBEACOPP in 2, miniCHOP in 1, pembrolizumab in 1, unknown 1. A non-anthracycline multiagent regimen was used in 10 pts, single-agent therapy was used in 2. End of therapy response was CR in 71, PR in 10, SD 1, PD in 5 and unknown in 29. 89 unplanned hospitalisations occurred in 58 of 116 pts who received front-line therapy. Of the 102 pts treated with an anthracycline, 53 required an unplanned hospital admission. Pneumonitis occurred in 19 pts, 17 had bleomycin exposure. Of 102 pts treated with an anthracycline, 9 developed a cardiomyopathy. The only factors associated with an unplanned hospitalisation were ECOG status (P=0.01, OR 3.22 [95%CI 1.33-7.81] for ECOG 1 vs 0) and anthracycline use (P=0.04, OR 4.15 [95%CI 1.1-15.64]). Median follow-up was 2.3y (range 0.01-9.39). Estimated 2y PFS was 64.7% (95% CI 54.8-73.0%), 2y OS 71.3% (95% CI 61.6-78.8%). Estimated 2y PFS for patients who received anthracycline was 70.1% (95% CI 59.5-78.5) versus 33% (95% CI 12.5%-55.6%) for those who did not. The 2y PFS of the 10 pts with cHL from Richter's transformation (RT) was similar to the non-RT cohort at 60% versus 65.1%, P=0.08. Of pts treated with curative intent, disease relapse occurred in 23/107 at a median of 1.2y (range 0.14-6.41). Fifty pts died, 21 from progressive cHL, 9 from solid tumour, 1 from infection, 11 from other causes, 6 from treatment-related mortality, 2 from secondary treatment complications (cardiomyopathy and acute leukaemia). Factors associated with an improved OS include receipt of anthracycline (P<0.01), lower ECOG (P<0.01), never smoking (P=0.02), no polypharmacy (P=0.02), receipt of bleomycin (P<0.01), normal albumin (P=0.01). In a multivariate analysis only age (HR 1.11; P<0.01), anthracycline use (HR 0.17; P<0.01) and smoking status (HR 2.19; 95% CI 0.98-4.83 P=0.05) were associated with OS. Conclusion: This Australian study highlights the characteristics and challenges of treating cHL in elderly patients and emphasises the importance and complications of anthracycline use. Despite these challenges, managing our elderly patients with curative chemotherapy can result in a good PFS/OS and our results are consistent with prior reports. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Cardiovascular Risk Factor Burden and Treatment Control in Patients With CKD: The Fukuoka Kidney Disease Registry (FKR) Study

Cardiovascular Risk Factor Burden and Treatment Control in Patients With CKD: The Fukuoka Kidney Disease Registry (FKR) Study